蛋白酵素
淀粉样前体蛋白分泌酶
淀粉样前体蛋白
跨膜蛋白
蛋白酶
化学
劈理(地质)
生物化学
β淀粉样蛋白
跨膜结构域
蛋白质前体
酶
肽
阿尔茨海默病
生物
基因
受体
疾病
古生物学
病理
医学
断裂(地质)
作者
Robert Vassar,Brian D. Bennett,Safura Babu‐Khan,Steve Kahn,Elizabeth A. Mendiaz,Paul Denis,David B. Teplow,Sandra L. Ross,Patricia Amarante,Richard Loeloff,Yi Luo,Seth Fisher,Janis Fuller,Steven Edenson,Jackson Lile,Mark A. Jarosinski,Anja Leona Biere,Eileen Curran,Teresa L. Burgess,Jean-Claude Louis
出处
期刊:Science
[American Association for the Advancement of Science]
日期:1999-10-22
卷期号:286 (5440): 735-741
被引量:3705
标识
DOI:10.1126/science.286.5440.735
摘要
Cerebral deposition of amyloid β peptide (Aβ) is an early and critical feature of Alzheimer's disease. Aβ generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: β-secretase and γ-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of β-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of β-secretase cleavage products, and these were cleaved exactly and only at known β-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of β-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as β-secretase. Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for β-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI